<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650127</url>
  </required_header>
  <id_info>
    <org_study_id>1474/6.00.00/2018</org_study_id>
    <nct_id>NCT03650127</nct_id>
  </id_info>
  <brief_title>Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study</brief_title>
  <acronym>P5</acronym>
  <official_title>Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Markus Perola</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Finnish Institute for Health and Welfare</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      P5.fi study - P4 together with a fifth 'P' and '.fi' for population health Finally&#xD;
      Implemented in Finland - studies the value of returning genetic and metabolomic risk&#xD;
      information in two diseases (coronary heart disease and type 2 diabetes) and one feature&#xD;
      (venous thromboembolism). The hypothesis of the study is that 1) combining genetic and&#xD;
      metabolic risk with traditional risk factors adds value to the personal risk assessment of&#xD;
      these diseases, 2) such risk information can be provided to individuals using a web based&#xD;
      user portal in an easily understandable and useful format, and 3) receiving genetic and&#xD;
      metabolomic risk information has an effect on the health of the study participants.&#xD;
&#xD;
      The study is a continuation of FinHealth 2017 -study, which involved more than 7,000 Finns&#xD;
      from around the country. The participants of FinHealth were invited to participate in P5.fi&#xD;
      -study. The new research utilises information, samples, and measurements obtained in the&#xD;
      FinHealth Study. Prospective clinical significance of selected genetic and metabolomic risk&#xD;
      scores will be studied in 30.000 Finnish individuals. The study will analyze the genetic and&#xD;
      metabolomic profile of the P5.fi participants and develop and test a protocol for returning&#xD;
      them health related risk information. The impact of the intervention will by followed up by&#xD;
      questionnaires and national health registers for five years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis</measure>
    <time_frame>Measure is assessed after a year from the start of the study.</time_frame>
    <description>Disease diagnosis observed from the national hospitalization and death registries.</description>
  </primary_outcome>
  <enrollment type="Actual">3449</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Deep Vein Thrombosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population of FinHealth 2017 -study represent the general population of Finland.&#xD;
        All participants are over 18 years of age and have been selected randomly from the&#xD;
        population registry. All FinHealth 2017 participants with DNA sample and permission for a&#xD;
        re-contact were invited to P5.fi study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Only participants of FinHealth 2017 -study are eligible for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Participants not part of FinHealth 2017 -study are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Perola, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Health and Welfare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Health and Welfare</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00271</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Finnish Institute for Health and Welfare</investigator_affiliation>
    <investigator_full_name>Markus Perola</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <keyword>Genetic risk score</keyword>
  <keyword>metabolic risk score</keyword>
  <keyword>health promotion</keyword>
  <keyword>web-based</keyword>
  <keyword>intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

